Why BGPT?
logo

Assess an author's data and outputs

See the raw experimental evidence behind an author's publications and reproducibility signals.







Press Enter ↡ to solve



    Fuel Your Discoveries




     Quick Explanation


    Haoran An β€” scientific strength snapshot
    Based on the provided body of work summary, An’s strongest signal is in materials/chemical engineering and computational biology adjacent themes, with multiple papers reporting quantitative, metric-driven results (e.g., diagnostic AUCs in a multi-dataset MASH study and large improvements in engineered biosystems such as ncAA incorporation ), suggesting competence in both wet-lab quantification and computational pipelines. However, the profile you provided contains substantial cross-domain breadth and many items are summarized without full methods/raw-data audits, limiting my ability to assess reproducibility depth from this dataset alone.



     Long Explanation


    Author Review: Haoran An

    Evidence used: the provided paper summaries + metric extracts you included (each with its DOI). Where the dataset is only a summary, I treat details like β€œreproducibility” and β€œmechanism” as partially assessed.

    Visual 1 β€” Diagnostic model performance (MASH biomarker panel)

    Training vs external validation AUCs for the reported seven-gene model.

    Visual 2 β€” Gene panel size & selection rule (as reported)

    What the summary claims: 34 MRDEGs β†’ 7 signature MRDEGs β†’ diagnostic panel.

    Visual 3 β€” Protein-engineering metric deltas (ncAA incorporation)

    Reported relative improvements for engineered PylRS variants (as summarized).

    1) What we can infer from the provided evidence

    • Computational-biomarker capability (human liver, MASH/MASLD context): the provided summary claims multi-dataset integration (5 GEO training sources), batch normalization, limma-based differential expression, robust rank aggregation to define metabolism-related DEGs, and multiple ML selectors (LASSO, SVM-RFE, random forest), culminating in a seven-gene diagnostic panel with reported AUCs of 0.915 (training), 0.979, and 0.966 in two external cohorts.
    • Quantitative wet-lab + ML for enzyme engineering (ncAA incorporation): the provided summary claims a machine-learning-guided variant search over the N-terminal tRNA-binding domain of PylRS, with reported improvements such as ~11Γ— SCS for a β€œCom1” design vs IFRS, ~30.8Γ— for β€œCom2” vs IFRS, and a maximal SCS fold change reported as ~101.9Γ— (and up to ~7.8Γ— for kcat/Km(tRNA)).
    • Cross-domain publication portfolio signal (from your provided list): your provided works span materials chemistry, bioinformatics, developmental biology, immune/tumor reviews, and more. This can indicate broad competence, but also makes β€œscientific rigor across domains” hard to audit without full text + methods + raw data links for each publication.

    2) Scientific strength: quality vs. uncertainty

    Known (supported by your provided excerpts): At least two of the included items report strong, quantitative outcomes: (i) a biomarker/diagnostic ML workflow with reported high AUCs across training and external cohorts and (ii) enzyme-engineering with ML-guided design and multiple validation modalities (reporters + LC-MS + binding/catalysis assays as summarized), yielding very large reported fold improvements .

    Uncertain (needs full-text/risk-of-bias audit):

    • For the MASH biomarker ML study, the strongest red-flag risk in many bioinformatics signature papers is that excellent AUCs can be driven by dataset-specific artifacts (batch, platform, demographic/clinical imbalance), even when cross-validation and external cohorts are used. Your excerpt explicitly flags heterogeneity, lack of stratification by gender/region, and reliance on public datasets . Without the full list of preprocessing decisions, normalization details, and model selection/thresholding procedures, I cannot verify robustness beyond the summary.
    • For the PylRS engineering study, very large fold changes raise the standard skepticism: are improvements stable across experimental contexts, and are there potential confounders between reporter fluorescence and actual aminoacylation/incorporation efficiency? Your excerpt states limitations including limited ability to extrapolate to unseen positions and that MD analyses used BocK rather than native pyrrolysine in some interpretations .

    3) Domain fit & potential blind spots from this provided snapshot

    • Methodological rigor appears metric-oriented in the excerpted items (AUC, fold-change, reported assay types). That’s a strength.
    • However, β€œmechanistic causal strength” is uneven across fields: diagnostic signatures and enzyme-activity improvements can be strong in prediction/performance but may not fully establish causal mechanisms (especially when mechanistic claims rely on indirect evidence).
    • Reproducibility depth is unknown here because we only have your summarized extract (not the full materials & methods, raw data availability, and independent replication results).

    4) How to falsify the implied claims (what would change the conclusion)

    • For the MASH diagnostic panel: the excerpt’s own falsification logic aligns with standard expectationsβ€”findings would be undermined if independent, diverse cohorts fail to show differential expression for the seven MRDEGs or if AUCs drop substantially (and if immune-infiltration correlations don’t replicate).
    • For the PylRS engineering: falsification would include inability to reproduce incorporation efficiency gains in additional backgrounds and substrates, or evidence that improvements are not due to the claimed mechanistic driver (e.g., tRNA-binding changes) when directly tested by appropriate kinetic readouts.

    5) Citation-metric note (from your provided profile data)

    Your provided author-profile fields include (verbatim from your prompt data) h-index / citations / paper count signals for multiple β€œHaoran An” identities in OpenAlex, plus a separate β€œHao-Yun An” summary (e.g., h-index values 18–20 with cited_by_count ~1295–1362 in OpenAlex matches). Because the identity-disambiguation is ambiguous in the data you supplied (multiple close matches), I cannot responsibly map these metrics to β€œHaoran An” without an explicit author-ID crosswalk.
    Practical critique: when bibliometric identity is uncertain, β€œcitation impact” comparisons can be misleading. This is a known failure mode in author-review workflows.


    Feedback:    

    Updated: May 01, 2026

     Top Data Sources ExportMCP


     Analysis Wizard



    Construct a small figure-ready table from the provided extracts (AUC training/validation and gene counts), then render Plotly charts and compute simple reliability summaries across cohorts.



     Hypothesis Graveyard


    A simple β€œmore docking/optimization = better enzyme” rule fails because the excerpted enzyme work highlights substrate/context dependence and limits of extrapolation (so gains can be architecture- and dataset-specific).


    A single immune-cell correlation with a biomarker gene is unlikely to be causal across cohorts; without stratified mechanistic validation, immune associations can be epiphenomenal (consistent with the diagnostic study’s need for stronger experimental validation).

     Science Art


    Author Review: Haoran An Science Art

     Science Movie


    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion








    Get Ahead With Science Insights

    Custom summaries of the latest cutting edge Science research. Every Friday. No Ads.


    My BGPT






     Trending